Clinical Trials Logo

Clinical Trial Summary

The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04537377
Study type Interventional
Source Vivet Therapeutics SAS
Contact Sonia Valero
Phone +33 1 83 81 17 10
Email info@vivet-therapeutics.com
Status Recruiting
Phase Phase 1/Phase 2
Start date September 3, 2021
Completion date March 2029

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06051734 - Early Detection of Cardiac Affection in Patients of Wilson's Disease
Active, not recruiting NCT02252380 - ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders N/A
Completed NCT01874028 - A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients Phase 1
Recruiting NCT05183165 - Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease N/A
Completed NCT00212355 - Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan. Phase 3
Recruiting NCT05493605 - Cardiac Involvement in Wilson's Disease N/A
Recruiting NCT03957720 - The Individual Therapy for Patients With Wilson's Disease Early Phase 1
Recruiting NCT05239858 - International Wilson's Disease Patient Registry (iWilson Registry)
Recruiting NCT04012658 - A Registered Cohort Study on Wilson's Disease
Completed NCT02552628 - WILSTIM - DBS (WILson STIMulation - Deep Brain Stimulation) N/A
Completed NCT06128954 - Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). Phase 1
Recruiting NCT05305872 - Gandouling in the Treatment of Wilson's Disease Phase 4
Recruiting NCT04212195 - Cohort Research on Wilson's Disease
Completed NCT01378182 - Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis N/A